Navigation Links
10% of U.S. Kids Using Cough Medicine Every Week
Date:5/3/2008

Researchers find decongestants and antihistamines taken most often

SATURDAY, May 3 (HealthDay News) -- Approximately one in 10 U.S. children uses one or more cough and cold medications during a given week, according to new research from Boston University.

While cough and cold medications for children are widely marketed in the United States, how frequently they are used had not been scientifically studied. This new finding, from researchers at Boston University's Slone Epidemiology Center, gives increased weight to recent revelations that cough and cold medication use can lead to serious adverse effects, including death.

"Given concerns about potential harmful effects and lack of evidence proving that these medications are effective in young children, the fact that 1-in-10 U.S. children is using one of these medications is striking," study author Dr. Louis Vernacchio, an assistant professor of epidemiology and pediatrics at Boston University School of Medicine, said in a prepared statement.

Yet, the researchers also reported positive news in children's use of cough syrup and other drugs. The overall use of cough and cold medications declined from 12.3 percent in 1999-2000 to 8.4 percent in 2005-2006, they found.

The findings were scheduled to be presented Saturday at the Pediatric Academic Societies meeting in Honolulu.

Researchers analyzed data gathered between 1999 and 2006 through a national telephone survey and considered all oral medicines approved by the U.S. Food and Drug Administration to treat children's coughs and colds.

In any given week, 10.1 percent of U.S. children took at least one cough and cold medication, the researchers found. In terms of active ingredients, most used were decongestants and antihistamines (6.3 percent each), followed by anti-cough medicines (4.1 percent) and expectorants (1.5 percent).

Children aged 2 to 5 used the medications most oft
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. Adverse housing conditions contribute to diabetes risk
3. Females avoid incest by causing male relatives to leave home
4. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
7. Using the Internet to Promote Exercise
8. Hazards of using crib bumper pads outweigh their benefits
9. Nosespray vaccine using aloe vera has exciting potential, researcher says
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Genetic test announced for suicidal ideation in patients using antidepressant drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
10% of U.S. Kids Using Cough Medicine Every Week
10% of U.S. Kids Using Cough Medicine Every Week
(Date:7/26/2008)...an farm, FDA announces , , FRIDAY, July...ering the first big clue in the nationwide salmone...ay that tainted jalapeno peppers had been definiti...d and Drug Administration gave the all-clear to ja...tes, but warned consumers to avoid any raw jalapen...
(Date:7/25/2008)...ter & Olsen LLP has filed a,class action lawsuit a...,"Company") (Nasdaq: ARTC ) and certain of its of...District of Texas on behalf of all persons or,enti...m January 24, 2008,through July 18, 2008 (the "Com... or entities who purchased call options or sold pu...
(Date:7/25/2008)...inancial results -, LAVAL, QC, July 25 /PRNewswir...DSS) today announced that it will host a conferenc...scuss its second quarter 2008,financial results. L...cial,results via news release at approximately 7:0...ll by telephone, dial 416-646-3095 or,1-800-814-48...
(Date:7/25/2008)...FirstCall/ -- Thoratec,Corporation (Nasdaq: THOR ...atory support therapies to save, support and resto...port its operating results for the second,quarter ...uly 31., The company will hold a conference call ...ivities to all interested parties at 1:30 p.m.,Pa...
Breaking Medicine News(10 mins):Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2
...skin of males than females. // Researchers at the ...of hairless mice to ultraviolet rays from a sun la...e WebMD, The mice underwent eight- to 10-minute ta...a week for six months. That was enough to give bot...
...of nutrition for many people around the globe. Thi...veral forms, it is the key ingredient for cooking ...ter just round the corner an animal rights group i...aign on Wednesday urging people not to eat eggs. &...
...ession for that ‘bronzed and beautiful’ look. But ...researchers. // According to a report published i... Health, the increases in people going in for tann...s is particularly so when considered in the light ...
...nts in the US, the public libraries in that countr...s. // In bad weather -- hot, cold, or wet -- most...ces. The local shelters push them out onto the s...g and, even when the weather is good, they are alr...
Other Medicine News:Health News:Sultans of Suntans Warned 2Health News:Public Libraries Turning into Shelters for the Homeless in the US 2
(Date:7/24/2008)...l/ -- MacroChem Corporation (OTC,Bulletin Board: M... trial,involving 37 patients who completed a 48-we...ety study of EcoNail, a topical antifungal,lacquer... The composite,primary efficacy endpoint of the tr...gy (negative fungal culture and negative KOH) and ...
(Date:7/23/2008)...uly print edition of Clinical ...23 /- A Roche Diagnostics-sponsored,p...type natriuretic peptide,(NT-proBNP) confirms the ...on in predicting the risk of cardiovascular advers...oidal anti-inflammatory drugs of,the COX inhibitor...
(Date:7/23/2008)...Pharma Inc., a company developing,breakthrough mol...mography,(PET) market, announced positive Phase I ...racer for myocardial perfusion imaging. BFPET is,F...plete Phase I clinical,development., BFPET is a P...w in the,heart (myocardial perfusion). Myocardial ...
(Date:7/23/2008).../ -- Dendreon Corporation,(Nasdaq: DNDN ) today a...toring Committee (IDMC) to review in October 2008 ...to the Company,s Phase 3 IMPACT (IMmunotherapy,for...D9902B) clinical trial,of PROVENGE(R) (sipuleucel-...ve cellular immunotherapy for the treatment of adv...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 1Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 2Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 3Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 1Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 2Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 3Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 5Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 6Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 7New Drug Shows Promise in Use With Coronary Stents 15457 1New Drug Shows Promise in Use With Coronary Stents 15457 2Motorola Biometric Identification System Selected by West Virginia State Police 2660 1Motorola Biometric Identification System Selected by West Virginia State Police 2660 2
...Serial Outpatient Infusion Study in Patients with,...he American,College of Cardiology 56th Annual Scie...RLEANS, March 25, 2007,/PRNewswire/ -- Scios Inc. ...Phase 2 study of nesiritide (NATRECOR(R)) showed a...te of death and,cardiorenal hospitalization at 12 ...
....J., March 25, 2007 /PRNewswire/ -- Once-daily,dos...tolvaptan, a,vasopressin receptor antagonist, was ... of acutely decompensated heart failure (ADHF),in ... without an,adverse effect on their long-term surv...ort- and long-term analyses of the,international l...
Other Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
Smooth colibri tip; In Titanium.
Fine .12mm Tip With 5mm Platform; In Titanium.
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium.
0.3mm tips; 9.5mm from tips to cross action; in Titanium.
Medicine Products: